Relationship between acute stroke outcome, aspirin resistance, and humoral factors

Journal of the Chinese Medical Association

Volumn 75, Issue 10, 2012, Pages 513-518

  Lai, Ping Tsun ^a   Chen, Shu Yi ^a,b   Lee, Yu Sun ^b   Ho, Yu Ping ^b   Chiang, Yi Ying ^a,b   Hsu, Hung Yi ^a,b,c  

^a TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Acute stroke; Aspirin; Outcome; Platelet aggregation; Platelet function tests

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ADRENALIN; C REACTIVE PROTEIN; CD40 LIGAND; COLLAGEN; D DIMER; FIBRINOGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PADGEM PROTEIN;

ADULT; AGED; ARTICLE; AUTOANALYZER; BODY MASS; CARTRIDGE; CEREBROVASCULAR ACCIDENT; DRUG EFFECT; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HUMAN; HUMORAL IMMUNITY; LABORATORY DEVICE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PLATELET FUNCTION ANALYZER; PROGNOSIS; PROTEIN BLOOD LEVEL; RANKIN SCALE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; C-REACTIVE PROTEIN; DRUG RESISTANCE; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; P-SELECTIN; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; STROKE; VON WILLEBRAND FACTOR;

EID: 84867896059     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2012.07.005     Document Type: Article

References (39)

1. Angiolillo D.J., Ueno M., Goto S. Basic principles of platelet biology and clinical implications. Circ J 2010, 74:597-607.
2. Lip G.Y., Blann A.D., Farooqi I.S., Zarifis J., Sagar G., Beevers D.G. Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to prognosis following acute stroke: The West Birmingham stroke project. Blood Coagul Fibrinolysis 2002, 13:339-347.
3. McColl B.W., Allan S.M., Rothwell N.J. Systemic infection, inflammation and acute ischemic stroke. Neuroscience 2009, 158:1049-1061.
4. Tsai N.W., Chang W.N., Shaw C.F., Jan C.R., Chang H.W., Huang C.R., et al. Levels and value of platelet activation markers in different subtypes of acute non-cardio-embolic ischemic stroke. Thromb Res 2009, 124:213-218.
5. Yip H.K., Liou C.W., Chang H.W., Lan M.Y., Liu J.S., Chen M.C. Link between platelet activity and outcomes after an ischemic stroke. Cerebrovasc Dis 2005, 20:120-128.
6. Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373:1849-1860. Antithrombotic Trialists' (ATT) Collaboration.
7. Grundmann K., Jaschonek K., Kleine B., Dichgans J., Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003, 250:63-66.
8. Berrouschot J., Schwetlick B., von Twickel G., Fischer C., Uhlemann H., Siegemund T., et al. Aspirin resistance in secondary stroke prevention. Acta Neurol Scand 2006, 113:31-35.
9. McCabe D.J., Harrison P., Mackie I.J., Sidhu P.S., Lawrie A.S., Purdy G., et al. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA. Platelets 2005, 16:269-280.
10. Schwammenthal Y., Tsabari R., Shenkman B., Schwartz R., Matetzky S., Lubetsky A., et al. Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome. Cerebrovasc Dis 2008, 25:355-361.
11. Alberts M.J. Platelet function testing for aspirin resistance is reasonable to do: yes!. Stroke 2010, 41:2400-2401.
12. Kretschmer V., Bade S., Weippert-Kretschmer M., Kratzer M.A. Measurement of primary haemostasis using a pressure clamp technique. Platelets 2001, 12:462-470.
13. Favaloro E.J. Clinical utility of the PFA-100. Semin Thromb Hemost 2008, 34:709-733.
14. Krasopoulos G., Brister S.J., Beattie W.S., Buchanan M.R. Aspirin " resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008, 336:195-198.
15. Reny J.L., De Moerloose P., Dauzat M., Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008, 6:444-450.
16. von Lewinski F., Riggert J., Paulus W. Towards a rationale of platelet aggregation monitoring in stroke prophylaxis?. J Stroke Cerebrovasc Dis 2009, 18:111-115.
17. Crescente M., Di Castelnuovo A., Iacoviello L., Vermylen J., Cerletti C., de Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008, 99:14-26.
18. Alberts M.J., Bergman D.L., Molner E., Jovanovic B.D., Ushiwata I., Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004, 35:175-178.
19. Adams H.P., Bendixen B.H., Kappelle L.J., Biller J., Love B.B., Gordon D.L., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993, 24:35-41.
20. Abaci A., Caliskan M., Bayram F., Yilmaz Y., Cetin M., Unal A., et al. A new definition of aspirin non-responsiveness by platelet function analyzer-100 and its predictors. Platelets 2006, 17:7-13.
21. Kleinig T.J., Vink R. Suppression of inflammation in ischemic and hemorrhagic stroke: therapeutic options. Curr Opin Neurol 2009, 22:294-301.
22. Song I.U., Kim J.S., Kim Y.I., Lee K.S., Jeong D.S., Chung S.W. Relationship between high-sensitivity C-reactive protein and clinical functional outcome after acute ischemic stroke in a Korean population. Cerebrovasc Dis 2009, 28:545-550.
23. Yeh E.T., Khan B.V. The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis. J Thromb Haemost 2006, 4:2308-2316.
24. Shantikumar S., Grant P.J., Catto A.J., Bamford J.M., Carter A.M. Elevated C-reactive protein and long-term mortality after ischaemic stroke: relationship with markers of endothelial cell and platelet activation. Stroke 2009, 40:977-979.
25. Welsh P., Barber M., Langhorne P., Rumley A., Lowe G.D., Stott D.J. Associations of inflammatory and haemostatic biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc Dis 2009, 27:247-253.
26. Feinberg W.M., Erickson L.P., Bruck D., Kittelson J. Hemostatic markers in acute ischemic stroke. Association with stroke type, severity, and outcome. Stroke 1996, 27:1296-1300.
27. Haapaniemi E., Tatlisumak T. Is D-dimer helpful in evaluating stroke patients? A systematic review. Acta Neurol Scand 2009, 119:141-150.
28. Poulsen T.S., Mickley H., Korsholm L., Licht P.B., Haghfelt T., Jorgensen B. Using the platelet function analyzer-100 for monitoring aspirin therapy. Thromb Res 2007, 120:161-172.
29. Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G., Huisman M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007, 167:1593-1599.
30. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001, 88:230-235.
31. Boncoraglio G.B., Bodini A., Brambilla C., Corsini E., Carriero M.R., Parati E.A. Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease. Clin Neurol Neurosurg 2009, 111:270-273.
32. Christiaens L., Ragot S., Mergy J., Allal J., Macchi L. Major clinical vascular events and aspirin-resistance status as determined by the PFA-100 method among patients with stable coronary artery disease: a prospective study. Blood Coagul Fibrinolysis 2008, 19:235-239.
33. Golanski J., Chlopicki S., Golanski R., Gresner P., Iwaszkiewicz A., Watala C. Resistance to aspirin in patients after coronary artery bypass grafting is transient: impact on the monitoring of aspirin antiplatelet therapy. Ther Drug Monit 2005, 27:484-490.
34. Yamazaki M., Uchiyama S., Iwata M. Measurement of platelet fibrinogen binding and p-selectin expression by flow cytometry in patients with cerebral infarction. Thromb Res 2001, 104:197-205.
35. Grau A.J., Weimar C., Buggle F., Heinrich A., Goertler M., Neumaier S., et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001, 32:2559-2566.
36. Choudhury A., Chung I., Blann A.D., Lip G.Y. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as indexes of platelet function in atrial fibrillation: a comparison of " healthy control subjects" and " disease control subjects" in sinus rhythm. J Am Coll Cardiol 2007, 49:1957-1964.
37. Watson T., Shantsila E., Lip G.Y. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009, 373:155-166.
38. Faraday N., Becker D.M., Yanek L.R., Herrera-Galeano J.E., Segal J.B., Moy T.F., et al. Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population. Am J Cardiol 2006, 98:774-779.
39. Lip G.Y., Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?. Cardiovasc Res 1997, 34:255-265.